India rejects BDR Pharma's bid to make generic of Bristol's Sprycel

11/1/2013 | Economic Times (India), The

The Indian Patent Office denied BDR Pharmaceuticals' compulsory licensing application to produce a generic copy of Bristol-Myers Squibb's cancer drug Sprycel, or dasatinib, because it said BDR did not make sufficient efforts to acquire a voluntary license for the drug. "The facts of the case indicate that BDR did not make enough attempts to seek a voluntary license from the innovator company, which went against them," said Chaitanya Prasad, controller general of patents. BDR called the decision unfair, while Bristol-Myers Squibb said "intellectual property protection is important" for innovation.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA